{
    "paper_id": "17de15d04f7a7643550666d2f0da773f5b7dc95c",
    "metadata": {
        "title": "",
        "authors": [
            {
                "first": "Didier",
                "middle": [],
                "last": "Raoult",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "AP-HM",
                    "location": {
                        "settlement": "Marseille",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Po-Ren",
                "middle": [],
                "last": "Hsueh",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "National Taiwan University College of Medicine",
                    "location": {
                        "settlement": "Taipei",
                        "country": "Taiwan"
                    }
                },
                "email": ""
            },
            {
                "first": "Stefani",
                "middle": [],
                "last": "Stefania",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Catania",
                    "location": {
                        "country": "Biological"
                    }
                },
                "email": ""
            },
            {
                "first": "Jean-Marc",
                "middle": [],
                "last": "Rolain",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "AP-HM",
                    "location": {
                        "settlement": "Marseille",
                        "country": "France"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "We are publishing a special issue dedicated to the coronavirus, in all its aspects of management and treatment. Indeed, in the 21st century, it is necessary to share data as quickly as possible, including the publication of preliminary data, so that in the time of care and management, the maximum should be done to help infected patients and decision-makers in strategies to fight this new virus [1] . This responds to recent recommendations and has the advantage over the pre-prints, which are currently available, of having been urgently reviewed by competent reviewers in the field, to assess their credibility. Thus, in order to meet modern needs for dissemination of data on emerging pathogens and disease, the combination of speed and credibility assessment becomes essential elements in the response against epidemics.",
            "cite_spans": [
                {
                    "start": 397,
                    "end": 400,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "ENGLISH VERSION"
        },
        {
            "text": "The response to the creation of a such special issue also takes into account the fact that not only the disease is emerging, but that it originates from \"emerging countries\", and giving everyone access to preliminary data from the Far East is a necessity for patient management in other areas. In particular, we see that a controversy has arisen in the use of repositioning treatments, such as chloroquine [2, 3] , for coronavirus, which justifies calling on those who have the most experience with this disease to communicate to the rest of the scientific world, in order to shed light on the choices to come. L'idea della pubblicazione di questo numero speciale tiene conto del fatto che non solo sta emergendo una nuova malattia, ma che questa proviene dai \"paesi emergenti\" facendo diventare importantissimo l'accesso ai dati preliminari dall'Estremo Oriente, In modo da far condividere la loro esperienza di gestione ai colleghi di altre aree del pianeta. In particolare, stiamo assistendo ad una controversia nell'uso e nel riposizionamento di alcuni trattamenti, un esempio \u00e8 la clorochina [2, 3] , per le infezioni sostenute da coronavirus, giustificando quindi il nostro appello verso coloro che hanno acquisito esperienze con questa malattia al fine di comunicare questa loro conoscenza al resto del mondo.Tutto questo aiuter\u00e0 a far luce sulle scelte in divenire.",
            "cite_spans": [
                {
                    "start": 406,
                    "end": 409,
                    "text": "[2,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 410,
                    "end": 412,
                    "text": "3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1097,
                    "end": 1100,
                    "text": "[2,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 1101,
                    "end": 1103,
                    "text": "3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "ENGLISH VERSION"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Coronavirus: keep sharing research",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Anonymous",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "578",
            "issn": "7793",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Chloroquine for the 2019 novel coronavirus SARS-CoV-2",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Colson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Rolain",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Chloroquine and hydroxychloroquine as available weapons to fight COVID-19",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Colson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Rolain",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Lagier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Brouqui",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "un num\u00e9ro sp\u00e9cial consacr\u00e9 au coronavirus (COVID-19), dans tous ses aspects de prise en charge et de traitement. En effet, au 21\u00e8me si\u00e8cle, il est n\u00e9cessaire de partager les donn\u00e9es aussi rapidement que possible, y compris par la publication de donn\u00e9es pr\u00e9liminaires, de fa\u00e7on \u00e0 ce que dans le temps du soin et de la prise en charge, le maximum puisse \u00eatre fait pour aider les patients infect\u00e9s et les preneurs de d\u00e9cisions dans les strat\u00e9gies de lutte contre ce nouveau virus. Ceci r\u00e9pond \u00e0 des recommandations r\u00e9centes et pr\u00e9sente l'avantage sur les pr\u00e9-print, qui sont actuellement disponibles, d'avoir \u00e9t\u00e9 review\u00e9s en urgence par des reviewers comp\u00e9tents du domaine, afin d'en \u00e9valuer la cr\u00e9dibilit\u00e9. Ainsi, pour r\u00e9pondre aux besoins modernes de diffusion des donn\u00e9es sur les pathog\u00e8nes \u00e9mergents, l'association de la vitesse et de l'\u00e9valuation de la cr\u00e9dibilit\u00e9 deviennent des \u00e9l\u00e9ments essentiels dans la r\u00e9ponse contre les \u00e9pid\u00e9mies. La r\u00e9alisation d'un tel numero sp\u00e9cial tient compte du fait que non seulement la maladie est \u00e9mergente, mais qu'elle est issue de pays \u00e9mergents, pour pouvoir donner \u00e0 tous l'acc\u00e8s aux donn\u00e9es pr\u00e9liminaires d'Extr\u00eame Orient ce qui est une n\u00e9cessit\u00e9 pour prendre en charge les malades dans d'autres pays du Monde. En particulier, on voit qu'une pol\u00e9mique est apparue au sujet de l'usage et du repositionnement de m\u00e9dicaments existants comme la Chloroquine ce qui justifie l'appel \u00e0 ceux qui ont le plus d'exp\u00e9rience dans le traitement de cette maladie afin d'\u00e9clairer sur les choix th\u00e9rapeutiques \u00e0 coronavirus, prendendo in considerazione lavori che includano ogni suo aspetto, dalla gestione al trattamento. In questo secolo \u00e8 sempre pi\u00f9 importante condividere i dati il pi\u00f9 rapidamente possibile, includendo nelle pubblicazioni anche risultati preliminari, che possano in qualche modo essere d'aiuto nel trattamento e nella gestione di questi pazienti,affiancandosi quindi e aiutando i responsabili delle decisioni strategiche da attuare per combattere questo nuovo virus[1]. Tutto questo risponde alle recenti raccomandazioni riguardanti la disseminazione rapida dei risultati e presenta il vantaggio -rispetto alle bozze di stampa attualmente disponibili, -di venire prontamente valutate da revisori competenti nel settore, per valutare la loro credibilit\u00e0. Pertanto, al fine di soddisfare le moderne esigenze di diffusione dei dati sui patogeni e le malattie emergenti, la combinazione di valutazione della velocit\u00e0 e della credibilit\u00e0 diventa un elemento essenziale nella risposta contro le epidemie.",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}